Skip to main content
OpenTrials
Completed

NCT Number: NCT06365580

Dose Escalation Study of Kylo-0603 in Healthy Subjects

This clinical trial is the first-in-human study of Kylo-0603. The purpose of this randomized, double-blind, placebo-controlled phase 1 study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and effect of food of Kylo-0603 in healthy Chinese adult subjects.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

The first affiliated hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310000, China

About this study

The study consists of three parts: single ascending doses (Part 1), food effect (Part 2) and multiple ascending doses (Part 3).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women aged 18 to 55 years old, inclusive;
  • Body mass index (BMI) between 19 kg/m2 and 30 kg/m2, inclusive;
  • Having no clinically significant disorder, condition or disease at screening and before first dosing;
  • Female subjects must not be able to get pregnant and male subjects must agree to adhere to contraception restrictions;
  • Willing to comply with protocol required visits and assessments, and provide written informed consent.

Exclusion criteria

  • History of cardiovascular, respiratory, digestive, liver, urinary, hematological, endocrine, metabolic, immune, cutaneous, or psychoneurotic diseases;
  • History of evidence of malignant tumor or Gilbert syndrome;
  • Positive screen of Hepatitis B surface antigen, hepatitis C virus, human immunodeficiency virus or syphilis infection;
  • History of tuberculosis infection;
  • History of alcohol abuse within 12 months before dosing;
  • History of drug abuse within 3 months before screening;
  • History of blood donations or blood loss of 400 ml and more within 3 months before dosing;
  • Pregnant or breast-feeding women;
  • Other exclusion criteria applied per protocol.

Treatment and study plan

Kylo-0603 capsule

Drug

Administrated orally.

Placebo

Drug

Administrated orally.

Primary outcomes

  1. incidence of adverse events

    Time frame: up to 3 weeks

Secondary outcomes

  1. Pharmacokinetics (PK) parameter of maximum observed concentration (Cmax)

    Time frame: up to 3 weeks

  2. PK parameter of time of maximum observed concentration (Tmax)

    Time frame: up to 3 weeks

  3. PK parameter of area under the concentration time curve (AUC)

    Time frame: up to 3 weeks

Sponsors and collaborators

Lead sponsor

Kylonova (Xiamen) Biopharma co., LTD.

Industry

Registry information

Official study title

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single and Multiple Ascending Doses of Kylo-0603 Capsules in Healthy Subjects

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Apr 15, 2024
Registry last updated
Oct 9, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.